An update on LAMA/LABA combinations for COPD
Drug and Therapeutics Bulletin · 2017-01 · 55 (1) · 2.2-5
DOI: 10.1136/dtb.2017.1.0451 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug and Therapeutics Bulletin, online erschienen am 05.01.2017. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Themen: COPD
Abstract (Originalsprache)
The management of symptoms of chronic obstructive pulmonary disease (COPD) typically involves the use of inhaled long-acting bronchodilators. Previously, we have reviewed the long-acting muscarinic antagonists (LAMAs) ▼aclidinium, 1 ▼glycopyrronium, 2 tiotropium 3 and ▼umeclidinium, 4 and the long-acting beta 2 agonists (LABAs) indacaterol, 5 ▼olodaterol, 6 and ▼vilanterol (in combination with fluticasone) in the management of COPD. 7 Four fixed-dose combinations of a LAMA with a LABA are now available, all indicated as maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD. Here, we provide a brief overview of the four combinations and consider the place of a LAMA/LABA in people with COPD and any factors that might help to choose between them.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
(2017). An update on LAMA/LABA combinations for COPD. Drug and Therapeutics Bulletin, 55(1), 2.2-5. https://doi.org/10.1136/dtb.2017.1.0451
Vancouver
An update on LAMA/LABA combinations for COPD. Drug and Therapeutics Bulletin. 2017;55(1):2.2-5. doi:10.1136/dtb.2017.1.0451
BibTeX
@article{euvimed2017,
title = {An update on LAMA/LABA combinations for COPD},
journal = {Drug and Therapeutics Bulletin},
year = {2017},
volume = {55},
number = {1},
pages = {2.2--5},
doi = {10.1136/dtb.2017.1.0451}
}
EUVIMED